🏅 FDA Orphan Designation
Lytgobi
futibatinib
Manufacturer: Taiho Oncology, Inc.
Indicated for:
FDA-Approved Indications (1)
Combined hepatocellular carcinoma and cholangiocarcinomaOrphan Designation
Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or …
Indications & Usage
Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
💙 Support Programs
View all →Lytgobi
Taiho Oncology, Inc.
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.